Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

201
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
201
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

161
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
161
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

327
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
327
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

182
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
182
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

191
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
191
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

498
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
498

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making CAR T-cell therapies more affordable.

Lancet (London, England)·2024
Same author

Medically assisted dying and cancer: a complex issue.

The Lancet. Oncology·2023
Same author

Africa needs to boost HPV vaccine uptake to stem rise in cervical cancer.

The Lancet. Oncology·2023
Same author

NHS embraces AI-assisted radiotherapy technology.

The Lancet. Oncology·2023
Same author

NHS England ends treatment break rule in bowel cancer.

The Lancet. Oncology·2023
Same author

Biomarker tests for targeted oncology therapies pose tricky regulatory challenges.

The Lancet. Oncology·2023
Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026
Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.9K

Pharmaceutical downsizing and oncology drug development

Kathryn Senior

    The Lancet. Oncology
    |January 10, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
    07:00

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

    Published on: August 11, 2017

    8.6K
    Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
    11:18

    Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

    Published on: January 23, 2011

    16.5K

    Related Experiment Videos

    Last Updated: Jan 27, 2026

    Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
    07:23

    Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

    Published on: October 20, 2023

    1.9K
    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
    07:00

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

    Published on: August 11, 2017

    8.6K
    Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
    11:18

    Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

    Published on: January 23, 2011

    16.5K